Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics Inc (ATXI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 955
  • Shares Outstanding, K 3,295
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,650 K
  • EBIT $ -6 M
  • EBITDA $ -6 M
  • 60-Month Beta -0.50
  • Price/Sales 0.68
  • Price/Cash Flow N/A
  • Price/Book 0.40
  • Price/Earnings ttm 0.38
  • Earnings Per Share ttm -0.95
  • Most Recent Earnings $-0.21 on 11/13/25
  • Next Earnings Date 03/30/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1500 +93.33%
on 02/24/26
0.3000 -3.33%
on 03/11/26
+0.0100 (+3.57%)
since 02/23/26
3-Month
0.1500 +93.33%
on 02/24/26
0.7900 -63.29%
on 12/24/25
-0.3800 (-56.72%)
since 12/23/25
52-Week
0.1500 +93.33%
on 02/24/26
0.9699 -70.10%
on 10/22/25
-0.0720 (-19.89%)
since 03/21/25

Most Recent Stories

More News
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE...

FBIO : 2.90 (-2.68%)
ATXI : 0.2900 (unch)
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

FBIO : 2.90 (-2.68%)
ATXI : 0.2900 (unch)
AXSM : 156.22 (-0.40%)
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with...

AZN : 185.28 (+0.66%)
ATXI : 0.2900 (unch)
AXSM : 156.22 (-0.40%)
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Developments

Avenue Therapeutics reports third-quarter results, highlighting progress on drug development for neurologic diseases and financial challenges.Quiver AI SummaryAvenue Therapeutics, Inc. announced its third-quarter...

ATXI : 0.2900 (unch)
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

ATXI : 0.2900 (unch)
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

FBIO : 2.90 (-2.68%)
ATXI : 0.2900 (unch)
S&P Futures Climb as Investors Weigh Economic Outlook, U.S. Bank Earnings on Tap

June S&P 500 futures (ESM23) are trending up +0.34% this morning after three major U.S. benchmark indices ended the regular session higher as market participants digested the latest batch of corporate...

NFLX : 91.45 (-2.07%)
GOOGL : 292.92 (-3.03%)
NVDA : 175.18 (-0.26%)
CVS : 72.03 (+1.04%)
BAC : 48.23 (+1.49%)
TYL : 340.22 (-2.54%)
JNJ : 234.38 (-0.44%)
ENVX : 4.99 (-0.60%)
GS : 833.92 (+0.32%)
TD : 93.51 (-0.13%)
STT : 126.85 (+2.94%)
LMT : 609.95 (-1.02%)
AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease

/PRNewswire/ -- AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the...

ATXI : 0.2900 (unch)
Pre-Market Brief: Stocks Mixed as Key U.S. Payrolls Data Looms

December S&P 500 futures (ESZ22) are trending down -0.12% this morning after three major US benchmark indices extended declines for the second successive trading session as investors digested remarks from...

DKNG : 23.15 (-3.38%)
NVDA : 175.18 (-0.26%)
APRN : 12.99 (-0.08%)
AMD : 203.60 (+0.45%)
ATXI : 0.2900 (unch)
ESZ22 : 3,871.47s (-0.66%)
LEVI : 18.51 (-0.59%)
Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)

NEW YORK, NY / ACCESSWIRE / December 15, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue Therapeutics...

ATXI : 0.2900 (unch)

Business Summary

Avenue Therapeutics, Inc. is a specialty pharmaceutical company. It acquires, licenses, develops and commercializes products principally for use in the acute/intensive care hospital setting. Avenue Therapeutics, Inc. is based in New York, United States.

See More

Key Turning Points

3rd Resistance Point 0.3433
2nd Resistance Point 0.3167
1st Resistance Point 0.3033
Last Price 0.2900
1st Support Level 0.2633
2nd Support Level 0.2367
3rd Support Level 0.2233

See More

52-Week High 0.9699
Fibonacci 61.8% 0.6567
Fibonacci 50% 0.5599
Fibonacci 38.2% 0.4632
Last Price 0.2900
52-Week Low 0.1500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.